Further amend the amendment in section 1 in that part designated "§2700-A." in subsection 3 by striking out all of the first indented paragraph (page 2, lines 27 to 36 in amendment) and inserting in its place the following:

'3.__Disclosure of clinical trials of prescription drugs.__ Beginning October 15, 2005, a manufacturer or labeler of prescription drugs that is required to report marketing costs for prescription drugs pursuant to section 2698-A shall post, with regard to those prescription drugs, on the publicly accessible Internet website of the federal__National Institutes of Health or its successor agency or another publicly accessible website the following information concerning any clinical trial that the manufacturer conducted or sponsored on or after October 15, 2002:'